BioSight
Companies
Eikon Therapeutics, Inc. logo

EIKN

NASDAQMILLBRAE, CA
Eikon Therapeutics, Inc.

Eikon Therapeutics is a clinical-stage biotech company developing small-molecule drug candidates targeting cancer and other diseases, with a pipeline including programs named EIK1001, EIK1003, EIK1004, and EIK1005 in clinical trials, alongside preclinical programs EIK1006 and ARv7. Based on the forward-looking statements in their 10-K filing, the firm is leveraging an internal technology platform to inform drug discovery and development across multiple therapeutic areas.

Price history not yet available for EIKN.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar